Search
Searching Content indexed under Patent by Norton Rose Fulbright Canada LLP ordered by Published Date Descending.
Links to Result pages
 
1 2 3 4 5 6 7 8 9 10 11 . . .  
>>Next
 
Title
Country
Organisation
Author
Date
1
Government Releases Final Amendments To The PMPRB's Patented Medicines Regulations To Lower The Prices Of Patented Medicines
The Government is moving forward with changes to the PMPRB intended to lower the prices of patented medicines in Canada
Canada
15 Aug 2019
2
Après un second coup d'œil, la CAF confirme le rejet de demande en contrefaçon dans un litige portant sur des dispositifs médicaux ophtalmiques
Dans TearLab Corporation c. I-MED Pharma Inc, 2019 FCA 179, la Cour d'Appel Fédérale (CAF) a confirmé le rejet de l'action en contrefaçon de brevet de TearLab contre I-MED.
Canada
19 Jul 2019
3
A Tearful Conundrum: FCA Affirms Dismissal Of Infringement Claim In Patent Suit Regarding Ophthalmic Medical Devices
In TearLab Corporation v I-MED Pharma Inc., the Federal Court of Appeal (FCA) upheld the dismissal of TearLab's patent infringement action against I-MED.
Canada
16 Jul 2019
4
Federal Court Of Appeal Agrees That The PMPRB Incorrectly Applied The Patent-Pertaining Analysis
The Federal Court of Appeal has provided new guidance on the proper approach to the "patent pertaining" analysis used by the Patented Medicine Prices Review Board, including on the identification of the medicine ...
Canada
11 Jul 2019
5
Patent Act Infringement Actions Cannot Be Joined To PM(NOC) Infringement Actions During NOC Prohibition Period
The Federal Court recently confirmed that an infringement action under the Patent Act cannot be joined with an infringement action under the Patented Medicines (Notice of Compliance) Regulations ...
Canada
1 Jul 2019
6
L'importance d'établir une stratégie de propriété intellectuelle
Bâtir une image de marque ou un portefeuille de brevets, c'est bien.
Canada
20 Jun 2019
7
CUSMA Implementation Bill Introduced
CUSMA provides more protections for biologic and innovative pharmaceuticals under Canadian law.
Canada
10 Jun 2019
8
IP Monitor - Federal Court Grants Interim Injunction In Patent Case
Interim and interlocutory injunctions are exceptional remedies, particularly in patent infringement cases.
Canada
27 May 2019
10
Federal Court Raises The Bar To Grant Protective Orders – Consent Of The Parties Is Not Sufficient
The court has the jurisdiction and the ability to enforce a protective agreement.
Canada
26 Mar 2019
11
Competition Bureau Publishes Final IP Enforcement Guidelines
On March 13, 2019, the Competition Bureau (Bureau) published a revised version of its IP Enforcement Guidelines (IPEGs).
Canada
20 Mar 2019
12
FCA Confirms Entirety Of Inventors' Conduct Is Relevant In Obviousness Analysis And Upholds Inventiveness Of Crystal Form Patent
The Federal Court of Appeal upheld the validity of Canadian Patent 2,436,668 which covers Form I ODV succinate (marketed as PRISTIQ) in two separate appeals by Apotex Inc. and Teva Canada Ltd, finding that the claims were novel and inventive.
Canada
21 Feb 2019
13
Top Headlines Of 2018
Last year ushered in a number of changes to the Canadian pharmaceutical and life sciences sector.
Canada
18 Jan 2019
14
FCA Confirms That Non-Infringing Alternative Must Be Legal And Objectively Economically Viable
The Federal Court of Appeal ("FCA") confirmed that in assessing the availability of a non-infringing alternative ("NIA") defence, the NIA must be legal and cannot infringe any patent, and its economic viability must be considered objectively.
Canada
3 Jan 2019
15
Further Trademark Amendments Are Here — Bill C-86 Is Given Royal Assent
Canada's core IP statutes have been amended by Bill C-86, which received Royal Assent as the Budget Implementation Act, 2018, No. 2, SC 2018, c 27 on December 14, 2018.
Canada
21 Dec 2018
16
Bill C-86 Receives Royal Assent, Bringing Amendments Across Canada's IP Statutes
The patent-law changes in Bill C-86 are not specifically directed at pharmaceutical patentees, but have the potential to affect this area of litigation.
Canada
19 Dec 2018
17
Two Generics, One Hearing: Federal Court Orders Common Trial On Patent Validity Issues In Section 6 Actions
The Federal Court has ordered that the trial of two actions brought under the post-CETA Patented Medicines (Notice of Compliance) Regulations (the Regulations), against two separate generics,
Canada
27 Nov 2018
18
What Is The Impact Of The USMCA On IP In Canada?
The US-Mexico-Canada Agreement (USMCA), which is set to replace NAFTA, concluded on September 30, 2018.
Canada
26 Nov 2018
20
ONCA Permits Pleading Amendments Asserting Validity Of Previously Invalidated Patent Following Nexium Decision
This decision of the Ontario Court of Appeal (ONCA) arises in the context of a novel action brought by Apotex seeking damages for the delayed market entry of its generic version of Sanofi's blockbuster ramipril drug.
Canada
22 Nov 2018
Links to Result pages
 
1 2 3 4 5 6 7 8 9 10 11 . . .  
>>Next